Digital health founders navigating the current venture capital landscape are facing intense pressure to prove they are sufficiently “AI-first,” prompting widespread market confusion over whether to pivot toward artificial intelligence or focus on core software mechanics. According to industry analyses, while capital continues to flow into healthcare technology, leaders across the sector are grappling to define what it actually means to be an AI-native company versus a traditional software provider that integrates machine learning tools into established workflows.
The rush for capital is unmistakable. Rock Health reported that AI-enabled companies captured 54% of all digital health funding in 2025. Simultaneously, data from KLAS showed that healthcare organizations deploying artificial intelligence grew from under half of respondents to more than two-thirds over the course of 2025, a trend mirrored in practice by firms like Menlo Ventures. This influx of money has created an urgent environment where startup founders must decide whether their current business models represent durable enterprises or merely timely solutions designed to catch a passing hype wave.
Behind the buzzwords, market observers categorize surviving companies into two distinct groups: AI-native startups that must rapidly evolve into defensible software businesses, and established software providers that need to reinforce their proprietary defenses with artificial intelligence almost as quickly. Neither path offers guaranteed security in a crowded marketplace, but industry veterans suggest that traditional software companies may possess a distinct structural advantage that gives them more time than prevailing market sentiment suggests.
Software companies typically own vital daily workflows, sitting squarely inside their clients’ operational routines while housing proprietary data and critical integrations. These elements form robust commercial moats that make a platform difficult for healthcare organizations to remove or replace. Vertical SaaS companies strive for this workflow depth because it elevates them to a system of record, protecting them from commodity software competition.
The Rising Bar for AI-Native Startups
In contrast, AI-native companies face a much steeper climb than public market enthusiasm implies. Investors routinely rush to back promising machine learning models, but momentum alone only provides a temporary head start. According to market analysts, companies built entirely on third-party models must quickly construct operational moats before they are reduced to minor features inside a larger competitor’s tech stack or dismissed as temporary point solutions during an era of widespread point solution fatigue.
This dynamic is already visible in specialized areas such as claims submission workflows. Specialized models can initially appear vastly superior to generic alternatives, but that value proposition remains fragile if the startup does not control the underlying data, the customer relationships, or the workflow itself. As healthcare buyers experience fatigue from managing countless single-purpose tools, the grace period for niche artificial intelligence applications continues to narrow rapidly.
This operational reality forces founders to answer a fundamental question regarding return on investment. If a business cannot consistently prove measurable ROI by controlling enough of the overall administrative or clinical system, its window for securing long-term enterprise contracts is closing. The market continues to reward AI-adjacent marketing bluster largely because the technology sector has witnessed similar hype cycles before, echoing previous revolutionary waves like the mobile-first transition and early web3 experimentation.
Drawing Lessons From Past Technology Waves
A decade ago, software companies often marketed themselves primarily on platform compatibility, such as functioning seamlessly on Apple hardware or serving as a specialized mobile electronic health record. While legacy enterprise platforms quickly absorbed those specific differentiators, forward-looking developers still captured meaningful market share during the transition. Industry participants view artificial intelligence similarly—as a versatile tool rather than an entire business model on its own.
Healthcare providers, health plans, and large employers are adopting a remarkably grounded view of artificial intelligence because their operating budgets and administrative costs demand practical solutions. Data from KLAS indicates that organizations are most willing to deploy machine learning where operational tasks are well-defined and financial or clinical risks remain manageable. Consequently, healthcare leaders are actively utilizing AI for routine administrative tasks, clinical transcription, and revenue cycle automation where the economic value is immediately clear, while showing far more hesitation toward advanced autonomous agentic tools.
Enterprise buyers in healthcare move deliberately, favoring tools that solve specific operational friction points over sweeping technological transformations. Founders who cut through the industry noise realize that core business fundamentals have not changed. The market ultimately rewards enterprises that demonstrate verifiable usage figures, strong customer retention, and strict domain control. Artificial intelligence is steadily becoming an ordinary utility much like mobile capability before it, meaning success depends less on whether a company is aggressively branded as AI-first and more on whether it uses machine learning to deepen its existing competitive moats.